Related Experiment Video
Updated: Oct 12, 2025
06:52
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
54.0K
A scalable, clinically severe pig model for Duchenne muscular dystrophy
Michael Stirm1,2, Lina Marie Fonteyne1,2, Bachuki Shashikadze3
1Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, 81377 Munich, Germany.
Disease Models & Mechanisms
|November 19, 2021
Summary
Researchers developed a new breeding cohort of Duchenne muscular dystrophy (DMD) pigs. These pigs exhibit DMD hallmarks and survive for several months, offering valuable resources for studying the disease and testing treatments.
Area of Science:
- Animal Models
- Genetics
- Biomedical Research
Background:
- Large-animal models are essential for Duchenne muscular dystrophy (DMD) research.
- Existing cloned DMD pigs (DMDΔ52) die before sexual maturity, limiting breeding and study duration.
Purpose of the Study:
- To generate and characterize a breeding cohort of DMDΔ52 pigs for extended research.
- To establish a resource for evaluating diagnostic tools and therapeutic strategies for DMD.
Main Methods:
- Generation of female DMD+/- carrier pigs through breeding.
- Intensive neonatal management to improve survival rates.
- Pathological, proteomic, and behavioral assessments of DMDΔ52 piglets.
Main Results:
- Successful breeding produced significant numbers of DMDY/- and DMD+/- piglets.
- DMDΔ52 pigs survived for 3-4 months, enabling statistically relevant studies.
- Confirmed DMD-like pathology, including progressive myocardial fibrosis, altered connexin-43 expression, reduced ejection fraction, and impaired cognitive ability.
Conclusions:
- The established DMDΔ52 pig cohort provides a valuable, long-term model for Duchenne muscular dystrophy.
- This resource facilitates the study of DMD pathogenesis and the preclinical testing of novel therapies.
- Standardized tissue repositories enhance research reproducibility and accelerate therapeutic development.
